CN110996957A - 用于治疗子宫肌瘤并减少月经失血的促性腺激素释放激素拮抗剂给药方案 - Google Patents

用于治疗子宫肌瘤并减少月经失血的促性腺激素释放激素拮抗剂给药方案 Download PDF

Info

Publication number
CN110996957A
CN110996957A CN201880050807.2A CN201880050807A CN110996957A CN 110996957 A CN110996957 A CN 110996957A CN 201880050807 A CN201880050807 A CN 201880050807A CN 110996957 A CN110996957 A CN 110996957A
Authority
CN
China
Prior art keywords
patient
day
weeks
compound
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880050807.2A
Other languages
English (en)
Chinese (zh)
Inventor
E·卢马耶
J-P·戈特兰德
O·波尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Obseva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obseva SA filed Critical Obseva SA
Publication of CN110996957A publication Critical patent/CN110996957A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201880050807.2A 2017-06-05 2018-06-05 用于治疗子宫肌瘤并减少月经失血的促性腺激素释放激素拮抗剂给药方案 Pending CN110996957A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515232P 2017-06-05 2017-06-05
US62/515,232 2017-06-05
PCT/EP2018/064767 WO2018224497A1 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss

Publications (1)

Publication Number Publication Date
CN110996957A true CN110996957A (zh) 2020-04-10

Family

ID=62636157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880050807.2A Pending CN110996957A (zh) 2017-06-05 2018-06-05 用于治疗子宫肌瘤并减少月经失血的促性腺激素释放激素拮抗剂给药方案

Country Status (18)

Country Link
US (2) US11759464B2 (https=)
EP (2) EP3634419B1 (https=)
JP (2) JP7292566B2 (https=)
KR (1) KR102884301B1 (https=)
CN (1) CN110996957A (https=)
AU (2) AU2018280741B2 (https=)
CA (1) CA3066188A1 (https=)
DK (1) DK3634419T3 (https=)
EA (1) EA201992812A1 (https=)
ES (1) ES3018358T3 (https=)
FI (1) FI3634419T3 (https=)
HR (1) HRP20250390T1 (https=)
HU (1) HUE070907T2 (https=)
MX (2) MX2019014482A (https=)
PL (1) PL3634419T3 (https=)
PT (1) PT3634419T (https=)
SG (1) SG11201911599XA (https=)
WO (1) WO2018224497A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10881659B2 (en) 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
KR102884301B1 (ko) 2017-06-05 2025-11-11 깃세이 야쿠힌 고교 가부시키가이샤 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
CN112261942A (zh) 2018-04-19 2021-01-22 艾伯维公司 治疗重度月经出血的方法
JP2021532160A (ja) * 2018-08-01 2021-11-25 アッヴィ・インコーポレイテッド エラゴリックスに関する投与計画
CA3117092A1 (en) 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
SG11202104053TA (en) * 2018-11-07 2021-05-28 ObsEva SA Compositions and methods for the treatment of estrogen-dependent disorders
CN114466665A (zh) * 2019-08-08 2022-05-10 奥布赛瓦股份公司 用于治疗雌激素依赖性病症的组合物和方法
AU2020325721A1 (en) * 2019-08-08 2022-03-03 ObsEva S.A. GnRH antagonists for the treatment of estrogen-dependent disorders
KR20210155350A (ko) 2020-06-15 2021-12-22 한상왕 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用
KR102738115B1 (ko) 2024-03-25 2024-12-05 한상왕 자궁근종 예방, 개선 또는 치료용 약학 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753557A (zh) * 2010-02-10 2012-10-24 橘生药品工业株式会社 稠合杂环衍生物的盐及其晶体
JP2016513708A (ja) * 2013-03-15 2016-05-16 アッヴィ・インコーポレイテッド 月経出血過多および子宮類線維腫の処置に使用するための組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109171B2 (en) 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
KR101384132B1 (ko) 2005-10-19 2014-04-10 깃세이 야쿠힌 고교 가부시키가이샤 축합 복소환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도
WO2014042176A1 (ja) 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
TWI746613B (zh) 2016-08-08 2021-11-21 日商橘生藥品工業股份有限公司 子宮內膜病症治療劑之用法及用量
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
KR102884301B1 (ko) 2017-06-05 2025-11-11 깃세이 야쿠힌 고교 가부시키가이샤 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
SG11202104053TA (en) 2018-11-07 2021-05-28 ObsEva SA Compositions and methods for the treatment of estrogen-dependent disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753557A (zh) * 2010-02-10 2012-10-24 橘生药品工业株式会社 稠合杂环衍生物的盐及其晶体
JP2016513708A (ja) * 2013-03-15 2016-05-16 アッヴィ・インコーポレイテッド 月経出血過多および子宮類線維腫の処置に使用するための組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVID F. ARCHER, M.D.等: "Elagolix for the management of heavy", 《FERTILITY AND STERILITY》 *
OBSEVA: "Annual Report 2016", 《HTTP://INVESTORS.OBSEVA.COM/FINANCIAL-REPORTS》 *

Also Published As

Publication number Publication date
EP4509173A3 (en) 2025-06-04
EP3634419B1 (en) 2025-01-29
JP2023078315A (ja) 2023-06-06
CA3066188A1 (en) 2018-12-13
KR20200024797A (ko) 2020-03-09
EP4509173A2 (en) 2025-02-19
HRP20250390T1 (hr) 2025-05-23
MX2019014482A (es) 2020-08-17
SG11201911599XA (en) 2020-01-30
PT3634419T (pt) 2025-04-04
PL3634419T3 (pl) 2025-06-09
AU2018280741A1 (en) 2020-01-30
JP2020522525A (ja) 2020-07-30
AU2024201694A1 (en) 2024-04-04
KR102884301B1 (ko) 2025-11-11
WO2018224497A1 (en) 2018-12-13
ES3018358T3 (es) 2025-05-16
HUE070907T2 (hu) 2025-07-28
FI3634419T3 (fi) 2025-05-02
US20200179390A1 (en) 2020-06-11
JP7292566B2 (ja) 2023-06-19
MX2023013582A (es) 2024-04-16
JP7485815B2 (ja) 2024-05-16
EP3634419A1 (en) 2020-04-15
US11759464B2 (en) 2023-09-19
US20240000785A1 (en) 2024-01-04
AU2018280741B2 (en) 2023-12-21
EA201992812A1 (ru) 2020-05-21
DK3634419T3 (da) 2025-03-31

Similar Documents

Publication Publication Date Title
JP7485815B2 (ja) 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画
US20240293414A1 (en) Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
WO2020094698A2 (en) Compositions and methods for the treatment of estrogen-dependent disorders
WO2021023876A1 (en) Gnrh antagonists for the treatment of estrogen-dependent disorders
EP3873465B1 (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
HK40116843A (en) Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
EA049129B1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери
HK40027583B (en) Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss
HK40027583A (en) Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss
HK40059353B (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
HK40059353A (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20221018

Address after: Nagano

Applicant after: KISSEI PHARMACEUTICAL Co.,Ltd.

Address before: Swiss Prang Eli Ute

Applicant before: ObsEva S.A.